Investigation of the immunomodulatory effects of Lactobacillus casei and Bifidobacterium lactis on Helicobacter pylori infection

Helicobacter

Volumn 13, Issue 3, 2008, Pages 183-190

  Zhang, Li ^a   Su, Ping ^a   Henriksson, Anders ^a   O'Rourke, Jani ^a   Mitchell, Hazel ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Bifidobacterium; Gastritis; Helicobacter pylori; Lactobacillus; Probiotics

Indexed keywords

BACTERIUM ANTIBODY; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 23 SUBUNIT P40; LAFTI B 94; LAFTI L 26; PROBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; BIFIDOBACTERIUM ANIMALIS; C57BL 6 MOUSE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; IMMUNOMODULATION; LACTOBACILLUS CASEI; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TREATMENT DURATION;

ANIMALS; BIFIDOBACTERIUM; FEMALE; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-1BETA; INTERLEUKIN-23; LACTOBACILLUS CASEI; MICE; MICE, INBRED C57BL; PROBIOTICS;

BIFIDOBACTERIUM; BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS; HELICOBACTER PYLORI; LACTOBACILLUS; LACTOBACILLUS CASEI; MUS;

EID: 43449132150     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2008.00595.x     Document Type: Article

References (32)

1. Graham DY, Lewg M, Klein PD, et al. Effect of treatment of Helicobacter-pylori infection on the long term recurrence of gastric or duodenal ulcer-a randomized, controlled-study. Ann Intern Med 1992 116 : 705 8.
2. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. IARC monographs on the evaluation of carcinogenic risks to humans. Lyon, France : IARC 1994 : 218 20.
3. Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma. New Engl J Med 1994 330 : 1267 71.
4. Mitchell HM. The epidemiology of Helicobacter pylori. Gastroduodenal disease and Helicobacter pylori. 1999 : 11 30.
5. Marshall BJ, Windsor HM. The relation of Helicobacter pylori to gastric adenocarcinoma and lymphoma: pathophysiology, epidemiology, screening, clinical presentation, treatment, and prevention. Med Clin N Am 2005 89 : 313.
6. McLoughlin R, Racz I, Buckley M, O'Connor HJ, O'Morain C. Therapy of Helicobacter pylori. Helicobacter 2004 9 : 42 8.
7. Kamiji MM, de Oliveira RB. Non-antibiotic therapies for Helicobacter pylori infection. Eur J Gastroen Hepat 2005 17 : 973 81.
8. Sgouras D, Maragkoudakis P, Petraki K, et al. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl Environ Microbio 2004 70 : 518 26.
9. Sgouras DN, Panayotopoulou EG, Martinez-Gonzalez B, Petraki K, Michopoulos S, Mentis A. Lactobacillus johnsonii La1 attenuates Helicobacter pylori-associated gastritis and reduces levels of proinflammatory chemokines in C57BL/6 mice. Clin Diagn Lab Immun 2005 12 : 1378 82.
10. Aiba Y, Suzuki N, Kabir AMA, Takagi A, Koga Y. Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. Am J Gastroenterol 1998 93 : 2097 101.
11. Pantoflickova D, Corthesy-Theulaz I, Dorta G, et al. Favourable effect of regular intake of fermented milk containing Lactobacillus johnsonii on Helicobacter pylori associated gastritis. Aliment Pharm Therap 2003 18 : 805 13.
12. Johnson-Henry KC, Mitchell DJ, Avitzur Y, Galindo-Mata E, Jones NL, Sherman PM. Probiotics reduce bacterial colonization and gastric inflammation in H. pylori-infected mice. Digest Dis Sci 2004 49 : 1095 102.
13. Kabir AMA, Aiba Y, Takagi A, Kamiya S, Miwa T, Koga Y. Prevention of Helicobacter pylori infection by lactobacilli in a gnotobiotic murine model. Gut 1997 41 : 49 55.
14. Cruchet S, Obregon MC, Salazar G, Diaz E, Gotteland M. Effect of the ingestion of a dietary product containing Lactobacillus johnsonii La1 on Helicobacter pylori colonization in children. Nutrition 2003 19 : 716 21.
15. Sakamoto I, Igarashi M, Kimura K, Takagi A, Miwa T, Koga Y. Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. J Antimicrob Chemoth 2001 47 : 709 10.
16. Sheu BS, Wu JJ, Lo CY, et al. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002 16 : 1669 75.
17. Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002 97 : 2744 9.
18. Michetti P, Dorta G, Wiesel PH, et al. Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion 1999 60 : 203 9.
19. Henriksson A, Su P, Zhang L, Mitchell H. Probiotics: current challenges and new opportunities. Asia Pac J Clin Nutr 2006 15 : S66.
20. Ulmer HM, Ganzle MG, Vogel RF. Effects of high pressure on survival and metabolic activity of Lactobacillus plantarum TMW1.460. Appl Environ Microbiol 2000 66 : 3966 73.
21. ®B94 in human faecal samples from a consumption trial. FEMS Microbiol Lett 2005 244 : 99 103.
22. ® L26 in the gastrointestinal tract of the mouse. Lett Appl Microbiol 2007 44 : 120 5.
23. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis - The updated Sydney System. Am J Surg Pathol 1996 20 : 1161 81.
24. Ferrero RL, Thiberge JM, Huerre M, Labigne A. Immune responses of specific-pathogen-free mice to chronic Helicobacter pylori (strain SS1) infection. Infect Immun 1998 66 : 1349 55.
25. Cassatella MA, Meda L, Bonora S, Ceska M, Constantin G. Interleukin-10 (Il-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes - evidence for an autocrine role of tumor-necrosis-factor and IL-1-beta in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med 1993 178 : 2207 11.
26. Wang P, Wu P, Siegel MI, Egan RW, Billah MM. Interleukin (IL)-10 inhibits nuclear factor kappa-B (Nf-kappa-B) activation in human monocytes - IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 1995 270 : 9558 63.
27. DEIios MM, Manghetti M, DeCarli M, et al. T helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease. J Immunol 1997 158 : 962 7.
28. Hida N, Shimoyama T, Neville P, Dixon MF, Axon ATR, Crabtree JE. Increased expression of IL-10 and IL-12 (p40) mRNA in Helicobacter pylori infected gastric mucosa: relation to bacterial cag status and peptic ulceration. J Clin Pathol 1999 52 : 658 64.
29. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000 13 : 715 25.
30. Shida K, Kiyoshima-Shibata J, Nagaoka M, Watanabe K, Nanno M. Induction of interleukin-12 by Lactobacillus strains having a rigid cell wall resistant to intracellular digestion. J Dairy Sci 2006 89 : 3306 17.
31. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10- deficient mice develop chronic enterocolitis. Cell 1993 75 : 263 74.
32. Chen WX, Shu DR, Chadwick V. Reduced colonization of gastric mucosa by Helicobacter pylori in mice deficient in interleukin-10. J Gastroen Hepatol 2001 16 : 377 83.